Cargando…

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine

The spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (CoV), a type I transmembrane envelope glycoprotein, consists of S1 and S2 domains responsible for virus binding and fusion, respectively. The S1 contains a receptor-binding domain (RBD) that can specifically bind to angio...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Yuxian, Zhou, Yusen, Liu, Shuwen, Kou, Zhihua, Li, Wenhui, Farzan, Michael, Jiang, Shibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2004
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092904/ https://www.ncbi.nlm.nih.gov/pubmed/15474494 http://dx.doi.org/10.1016/j.bbrc.2004.09.106

Ejemplares similares

A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2013)

Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2022)

Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity
por: Du, Lanying, et al.
Publicado: (2009)

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients
por: Cao, Zhiliang, et al.
Publicado: (2010)

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine
por: He, Yuxian, et al.
Publicado: (2006)

Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry
por: He, Yuxian, et al.
Publicado: (2004)

Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model
por: Du, Lanying, et al.
Publicado: (2007)

The spike protein of SARS-CoV — a target for vaccine and therapeutic development
por: Du, Lanying, et al.
Publicado: (2009)

Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines
por: Du, Lanying, et al.
Publicado: (2006)

Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines
por: He, Yuxian, et al.
Publicado: (2005)

A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity
por: He, Yuxian, et al.
Publicado: (2006)

Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice
por: Liu, Xianglei, et al.
Publicado: (2020)

Immunogenicity of SARS-CoV: the Receptor-Binding Domain of S Protein is a Major Target of Neutralizing Antibodies
por: He, Yuxian
Publicado: (2006)

Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC
por: Du, Lanying, et al.
Publicado: (2013)

Quantitative comparison of the efficiency of antibodies against S1 and S2 subunit of SARS coronavirus spike protein in virus neutralization and blocking of receptor binding: Implications for the functional roles of S2 subunit
por: Zeng, Fanya, et al.
Publicado: (2006)

Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain
por: Chi, Xiaojing, et al.
Publicado: (2020)

Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
por: Ma, Huan, et al.
Publicado: (2021)

Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells
por: Du, Lanying, et al.
Publicado: (2009)

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus
por: Tang, Jian, et al.
Publicado: (2015)

A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding
por: Yang, Jing, et al.
Publicado: (2022)

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
por: Tian, Xiaolong, et al.
Publicado: (2020)

Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: Implications for a subunit vaccine
por: Zakhartchouk, Alexander N., et al.
Publicado: (2007)

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
por: Wrapp, Daniel, et al.
Publicado: (2020)

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
por: Wrapp, Daniel, et al.
Publicado: (2020)

Structures of Omicron spike complexes and implications for neutralizing antibody development
por: Guo, Hangtian, et al.
Publicado: (2022)

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
por: Cerutti, Gabriele, et al.
Publicado: (2021)

A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants
por: Haslwanter, Denise, et al.
Publicado: (2021)

Potent Neutralization of Botulinum Neurotoxin/B by Synergistic Action of Antibodies Recognizing Protein and Ganglioside Receptor Binding Domain
por: Chen, Changchun, et al.
Publicado: (2012)

Sub-Domains of Ricin’s B Subunit as Targets of Toxin Neutralizing and Non-Neutralizing Monoclonal Antibodies
por: Yermakova, Anastasiya, et al.
Publicado: (2012)

A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein
por: Li, Yan, et al.
Publicado: (2015)

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
por: Chi, Xiangyang, et al.
Publicado: (2020)

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
por: Kim, Cheolmin, et al.
Publicado: (2021)

Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants
por: Chen, Liqing, et al.
Publicado: (2022)

A novel single-domain antibody multimer that potently neutralizes tetanus neurotoxin
por: de Smit, Hans, et al.
Publicado: (2021)

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines
por: Ma, Cuiqing, et al.
Publicado: (2014)

Recombinant subunits of SARS‐CoV‐2 spike protein as vaccine candidates to elicit neutralizing antibodies
por: Noorabad Ghahroodi, Faezeh, et al.
Publicado: (2022)

Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody
por: Piepenbrink, Michael S., et al.
Publicado: (2022)

Receptor-binding domain-based subunit vaccines against MERS-CoV
por: Zhang, Naru, et al.
Publicado: (2015)

Spatial location of neutralizing and non-neutralizing B cell epitopes on domain 1 of ricin toxin’s binding subunit
por: Rong, Yinghui, et al.
Publicado: (2017)

Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies
por: Du, Lanying, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_skckdpt2ubuiiqru3oe5v5kl3h